Insulin glargine biosimilar - Wockhardt

Drug Profile

Insulin glargine biosimilar - Wockhardt

Alternative Names: Glaritus; Glaritus Cart; Glaritus DispoPen

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Wockhardt
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase antizyme stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 26 Aug 2013 Launched for Type-1 diabetes mellitus in Nepal, Sri Lanka and Tanzania (SC) after August 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top